The Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer Market.

Some of the key takeaways from the Non-Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 
• Non-Small Cell Lung Cancer companies working in the treatment market are J INTS BIO BIO CO.,LTD., Mirati Therapeutics, MediLink Therapeutics Co., Ltd., Cellular Biomedicine Group, Shenzhen TargetRx, Inc., Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment 

• Emerging Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- JIN-A03, MRTX1133, YL202, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others are expected to have a significant impact on the Non-Small Cell Lung Cancer market in the coming years. 
• In June 2023, Qilu Pharmaceutical showcased a trials in Progress poster presentation at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023). The presentation focused on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody designed for immunotherapy, detailing its involvement in two Phase III clinical studies for non-small cell lung carcinoma (NSCLC).
• In May 2023, Summit Therapeutics disclosed the enrollment of the inaugural patient in the Phase III HARMONi trial within the United States. HARMONi, a multiregional, randomized, double-blinded study, aims to assess the safety and effectiveness of ivonescimab in combination with chemotherapy for individuals diagnosed with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This study specifically targets patients who have experienced progression after undergoing treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) like osimertinib.
• In May 2023, Gilead Sciences and Arcus Biosciences provided revised findings from an interim analysis of the ARC-7 trial involving individuals with first-line, metastatic non-small cell lung cancer (NSCLC) showcasing PD-L1 tumor proportion score (TPS) of 50% but lacking epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. The progression-free survival curves exhibited an early divergence in both treatment arms involving domvanalimab from the zimberelimab arm, a separation that persisted consistently. These outcomes further endorse the potential therapeutic advantages associated with inhibiting the TIGIT pathway.
• In January 2023, Novocure disclosed that the LUNAR study, assessing the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard therapies for stage 4 non-small cell lung cancer (NSCLC) after progression post platinum-based therapy, successfully achieved its primary endpoint.
• In December 2022, The FDA in the United States has provided accelerated approval to Mirati’s Krazati (adagrasib), a targeted therapy designed for adult patients diagnosed with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
• In December 2022, Novartis Pharmaceuticals commenced an open-label Phase II trial to assess the effectiveness and safety of JDQ443 as a single-agent treatment in the first-line setting for patients diagnosed with locally advanced or metastatic KRAS G12C mutation.
• In June 2022, Novartis Pharmaceuticals started a Phase III trial, employing a randomized, controlled, open-label design. The study aims to compare the effectiveness and safety of JDQ443 against docetaxel in individuals previously treated for locally advanced or metastatic KRAS G12C mutant Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer Overview

Non-small cell lung cancer (NSCLC) is a condition where normal lung cells grow abnormally and multiply quickly, resulting in the formation of a lesion, nodule, or tumor. These lesions may appear anywhere on the lungs and may be cancerous or benign.

Get a Free Sample PDF Report to know more about Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight

Emerging Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• JIN-A03: J INTS BIO BIO CO.,LTD.
• MRTX1133: Mirati Therapeutics
• YL202: MediLink Therapeutics Co., Ltd.
• C-TIL051: Cellular Biomedicine Group
• TGRX-326: Shenzhen TargetRx, Inc.
• LN-145: Iovance Biotherapeutics
• RMC-4630: Revolution Medicines, Inc.
• GEN1046: Genmab
• Retifanlimab: Incyte Corporation
• DS-1062a: Daiichi Sankyo
• JDQ443: Novartis Pharmaceuticals

Non-Small Cell Lung Cancer Route of Administration

Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Non-Small Cell Lung Cancer Molecule Type

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

• Non-Small Cell Lung Cancer Assessment by Product Type
• Non-Small Cell Lung Cancer By Stage and Product Type
• Non-Small Cell Lung Cancer Assessment by Route of Administration
• Non-Small Cell Lung Cancer By Stage and Route of Administration
• Non-Small Cell Lung Cancer Assessment by Molecule Type
• Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s Non-Small Cell Lung Cancer Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Small Cell Lung Cancer product details are provided in the report. Download the Non-Small Cell Lung Cancer pipeline report to learn more about the emerging Non-Small Cell Lung Cancer therapies

Some of the key companies in the Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for Non-Small Cell Lung Cancer are – F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others.

Non-Small Cell Lung Cancer Pipeline Analysis:

The Non-Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.
• Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Small Cell Lung Cancer drugs and therapies

Non-Small Cell Lung Cancer Pipeline Market Drivers

• Increasing prevalence of non-small cell lung cancer, increasing launch of pipeline therapies are some of the important factors that are fueling the Non-Small Cell Lung Cancer Market.

Non-Small Cell Lung Cancer Pipeline Market Barriers

• However, high cost of therapies entering the market, requirement of adequate reimbursement policies for NSCLC drugs and other factors are creating obstacles in the Non-Small Cell Lung Cancer Market growth.

Scope of Non-Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Non-Small Cell Lung Cancer Companies: J INTS BIO BIO CO.,LTD., Mirati Therapeutics, MediLink Therapeutics Co., Ltd., Cellular Biomedicine Group, Shenzhen TargetRx, Inc., Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis, and others
• Key Non-Small Cell Lung Cancer Therapies: JIN-A03, MRTX1133, YL202, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others
• Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Non-Small Cell Lung Cancer Report Introduction

2. Non-Small Cell Lung Cancer Executive Summary

3. Non-Small Cell Lung Cancer Overview

4. Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. Non-Small Cell Lung Cancer Pipeline Therapeutics

6. Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. Non-Small Cell Lung Cancer Preclinical Stage Products

10. Non-Small Cell Lung Cancer Therapeutics Assessment

11. Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Small Cell Lung Cancer Key Companies

14. Non-Small Cell Lung Cancer Key Products

15. Non-Small Cell Lung Cancer Unmet Needs

16 . Non-Small Cell Lung Cancer Market Drivers and Barriers

17. Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services